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ABSTRACT Human cytomegalovirus (HCMV) is the leading cause of congenital viral
infection, and developing a prophylactic vaccine is of high priority to public health.
We recently reported a replication-defective human cytomegalovirus with restored
pentameric complex glycoprotein H (gH)/gL/pUL128-131 for prevention of congeni-
tal HCMV infection. While the quantity of vaccine-induced antibody responses can
be measured in a viral neutralization assay, assessing the quality of such responses,
including the ability of vaccine-induced antibodies to cross-neutralize the ﬁeld
strains of HCMV, remains a challenge. In this study, with a panel of neutralizing anti-
bodies from three healthy human donors with natural HCMV infection or a vacci-
nated animal, we mapped eight sites on the dominant virus-neutralizing antigen—
the pentameric complex of glycoprotein H (gH), gL, and pUL128, pUL130, and
pUL131. By evaluating the site-speciﬁc antibodies in vaccine immune sera, we dem-
onstrated that vaccination elicited functional antiviral antibodies to multiple neutral-
izing sites in rhesus macaques, with quality attributes comparable to those of CMV
hyperimmune globulin. Furthermore, these immune sera showed antiviral activities
against a panel of genetically distinct HCMV clinical isolates. These results high-
lighted the importance of understanding the quality of vaccine-induced antibody re-
sponses, which includes not only the neutralizing potency in key cell types but also
the ability to protect against the genetically diverse ﬁeld strains.
IMPORTANCE HCMV is the leading cause of congenital viral infection, and develop-
ment of a preventive vaccine is a high public health priority. To understand the
strain coverage of vaccine-induced immune responses in comparison with natural
immunity, we used a panel of broadly neutralizing antibodies to identify the immu-
nogenic sites of a dominant viral antigen—the pentameric complex. We further
demonstrated that following vaccination of a replication-defective virus with the re-
stored pentameric complex, rhesus macaques can develop broadly neutralizing anti-
bodies targeting multiple immunogenic sites of the pentameric complex. Such anal-
yses of site-speciﬁc antibody responses are imperative to our assessment of the
quality of vaccine-induced immunity in clinical studies.
KEYWORDS human cytomegalovirus, strain coverage, pentameric complex, epitope
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Human cytomegalovirus (HCMV) is ubiquitous in the human population. WhileHCMV infection is, in general, asymptomatic in healthy individuals, it can cause
severe diseases in immunocompromised patients, such as transplant recipients under
immunosuppression. HCMV is also recognized as the leading cause of in utero viral
infection, estimated to occur in approximately 0.64% of pregnancies in the United
States (1). Congenital HCMV transmission can occur following primary infection in
HCMV-seronegative mothers or nonprimary infection in HCMV-seropositive women (2).
Although the majority of infected newborns have no clinical presentation of infection
at birth, congenital HCMV infection can lead to neurodevelopmental sequelae in 12 to
25% of infected children, with manifestations that include sensorineural hearing loss
and learning disabilities. No vaccine is yet available despite the fact that the Institute
of Medicine has assigned the development of a prophylaxis against congenital HCMV
to the highest category of vaccine priority since 1999 (3).
Preconceptional maternal immunity from natural HCMV infection is associated with
a 69% reduction in the risk of maternal-fetal transmission (4). In addition, HCMV-
seropositive women with a child in day care are protected against secondary infection
from HCMV shed by their children (5). These observations indicate that natural HCMV
immunity is protective against HCMV transmission in both vertical and horizontal
settings; this notion has been adopted as the rationale for the design and development
of live attenuated HCMV vaccines, such as the Towne vaccine (6–8). However, the
immunity from naturally acquired infection may not provide complete protection
against superinfection (9). Healthy seropositive women can acquire secondary infec-
tion, diagnosed either on the basis of viral shedding or by inference from serological
responses to antigens different from those induced by their prior HCMV infection (10).
Importantly, superinfection in women can lead to congenital transmission (11, 12), and
children born with such congenital infections can develop sequelae similar to, but
usually milder than, those caused by primary maternal infection (13, 14). The lack of
complete protection by natural immunity may be due to defective host cellular
immunity to HCMV, as documented in transplant recipients under immunosuppression.
It may also be due to exposure to viral inocula of high infectivity, such as those found
in the urine and saliva of toddlers (15). Lastly, antiviral antibodies induced by natural
infection may have strain speciﬁcity, and under this circumstance, the preconceptional
maternal immunity may not be effective to protect against the congenital transmission
of a different HCMV strain. Understanding the strain coverage of antibody responses
has important implications for vaccine development.
HCMV is a double-stranded DNA virus with a genome capacity to encode at least 20
glycoproteins (16, 17). Entry of HCMV requires the concerted efforts of multiple
glycoprotein complexes. Glycoprotein B (gB) is a class III fusion protein (18–20). Its
fusogenic activity must be triggered via interaction with complexes containing glyco-
proteins H (gH) and L (gL) (18, 21, 22). A trimeric complex that includes gO (gH/gL/gO)
mediates viral entry into ﬁbroblasts, and recent reports suggest that gH/gL/gO might
be involved in viral entry into all cell types (23–25). The pentameric complex composed
of gH/gL bound with pUL128, pUL130, and pUL131 determines viral tropism for
epithelial cells, endothelial cells, and leukocytes, most likely through a receptor-
mediated endocytosis pathway (20, 26–31). In vitro characterization of puriﬁed mono-
clonal antibodies (MAbs) reveals two categories of antiviral antibodies: one neutralizes
infection of epithelial cells and predominantly recognizes epitopes located on the
pentameric complex, whereas the other neutralizes infection of ﬁbroblasts as well as
epithelial cells and recognizes epitopes located either on gB or the gH/gL/gO complex
(27, 32–35). It is unknown which category of antibodies is more important in preventing
HCMV infection in vivo.
We recently reported a vaccine comprised of a replication-defective AD169 variant
strain in which the pentameric complex was restored. The candidate, named V160, is
currently under clinical evaluation and has been shown capable of eliciting both
humoral and cell-mediated immune responses in preclinical animal models (36). Im-
portantly, it is designed to present all relevant antigens, including the pentameric
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complex, to the immune system in their natural conformations. To address the issue of
strain coverage by V160, we assembled a panel of neutralizing MAbs targeting the
pentameric complex. Derived from one vaccinated rabbit and three naturally infected
healthy human donors, these MAbs were used as probes for the identiﬁcation of eight
immunogenic sites on the pentameric complex. Antibodies with speciﬁcity to seven of
these sites can neutralize a panel of HCMV primary isolates. Furthermore, immune sera
from V160-vaccinated rhesus macaques were capable of competing against these
neutralizing MAbs, with effective strain coverage as assessed by neutralization.
RESULTS
Biochemical properties of the pentamer-speciﬁc antibodies. Previously, we iden-
tiﬁed 11 elite neutralizing MAbs from a vaccinated rabbit that recognized the penta-
meric complex (27). Later, we identiﬁed and cloned 10 antibodies based on neutral-
ization from memory B cells isolated from three healthy human donors with natural
HCMV infection, and they were found to be pentamer-speciﬁc MAbs. We assembled
these neutralizing MAbs, including 10 human and 11 rabbit MAbs, in order to investi-
gate unique neutralizing epitopes on this antigen complex.
We ﬁrst conﬁrmed by ﬂow cytometry that the selected MAbs from the panel can
recognize the pentameric complex in its native form on viral particles (37). V160 virus,
restored with pentameric complex expression, can be labeled by all the MAbs tested
(Fig. 1A). In contrast, AD169 virus, which lacks the expression of the pentameric
complex, cannot be labeled by most MAbs except 58.5 and 3-15 (Fig. 1B). This result
suggested that there exist some common epitopes between the gH/gL/gO and the
pentameric complex.
To better understand the antibody speciﬁcity to the common gH/gL stalk or a region
unique to the pentameric complex, we tested the binding of these MAbs to the soluble
forms of pentameric complex gH/gL/pUL128-131 (where pUL128-131 represents pUL128,
pUL130, and pUL131) and the gH/gL dimer, which are referred to, respectively, as the
pentamer and the dimer. Both recombinant complexes were previously demonstrated
to retain the conformational neutralizing epitopes as antigens comparable to the
membrane-bound forms (38). The relative afﬁnities of these MAbs to the antigens were
assessed and calculated as the effective concentration of IgG needed to achieve 50%
of maximal signal in ELISA (EC50). Nine antibodies could bind to both the pentamer and
the dimer (Fig. 1C), suggesting their speciﬁcity to the gH/gL portion of the complex,
and eight could bind only to the pentamer, suggesting their speciﬁcity to an epitope
involving at least one of the three components of pUL128-131. Four antibodies (15.1,
58.5, 223.4, and 347.3) did not react to either the pentamer or the dimer in ELISA. In
addition, it is worth noting that two gH/gL binders, 1-32 and 70.7, did not label AD169
virus (Fig. 1A and B), even though these two epitopes should in theory present in the
gH/gL/gO complex. Thus, the inability of antibodies 1-32 and 70.7 to react to AD169
virus suggested that their epitopes on the gH/gL/gO complex were not readily acces-
sible on the viral envelope, possibly due to the interference of gO.
We then measured the reactivity of these MAbs to denatured viral proteins by
Western blotting, with the assumption that viral proteins, after treatment with deter-
gent and reducing agent, would be devoid of any conformational epitope. In Fig. 1D,
none of 17 MAbs reacted to any viral proteins, suggesting that they likely targeted
conformational epitopes. Four MAbs (15.1, 58.5, 223.4, and 347.3) reacted to an antigen
of about 125 kDa from denatured V160 virus in Western blots. These MAbs were
subsequently identiﬁed to react to the linear epitopes located at gH residues 26 to 43
that are speciﬁc to AD169 (data not shown). This result was consistent with the
observation that these MAbs did not react to either the pentamer or the dimer, since
both recombinant complexes used in ELISA were constructed with the gH based on the
Towne strain amino acid sequence (27).
Mapping the immunogenic sites by antibody binding competition. To further
group this panel of antibodies on the basis of their recognition sites, we used biolayer
interferometry to measure the pairwise antibody binding competition. The competition
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results unveiled seven unique immunogenic sites of the pentamer (Table 1). Among the
seven immunogenic sites, only site 5 partially overlapped with site 6, while no com-
petition was observed among sites 1, 2, 3, 4, 6, and 7, suggesting that these sites
contain nonoverlapping epitopes. We did not include MAb 1-125 in this experiment
since our earlier experiment using individual biotinylated MAbs as probes in compe-
tition ELISA showed that MAb 1-125 competed effectively with site 2 antibodies 1-85
and 1-150 (data not shown).
Epitope mapping by electron microscopy (EM). To conﬁrm and map the multiple
immunogenic sites on the pentamer revealed by biochemical characterizations, we
analyzed negative-staining EM two-dimensional (2D) class averages of the pentamer
bound by representative antibodies from sites 1 to 7 (Fig. 2). The 2D class averages
illustrated that the free pentamer contained three distinguishable domains with a
curved domain 1 loosely connected to a stalk region of domains 2 and 3, approximately
4 nm and 7 nm in length, respectively. We discovered that Fab 270.7 bound to the
P
ar
tic
le
 C
ou
nt
s
Pa
rti
cl
e 
C
ou
nt
s
Fluorescence Intensity Fluorescence Intensity
V160 AD169
0
200
400
600
800
1,000
1.E+02 1.E+03 1.E+04 1.E+05 1.E+06
2-25
1-85
1-103
57.4
1-32
70.7
3-15
58.5
Control
200
0
400
600
800
1,000
1.E+02 1.E+03 1.E+04 1.E+05 1.E+06
2-25
1-85
1-103
57.4
1-32
70.7
3-15
58.5
Control
A B
0.1
1.0
10.0
100.0
2-
25
2-
18
1-
85
1-
12
5
1-
15
0
1-
10
3
57
.4
27
6.
1
70
.7
12
4.
4
27
0.
7
31
6.
2
32
4.
4
1-
32
3-
7
3-
7
3-
15
3-
16
15
.1
58
.5
22
3.
4
34
7.
3
PENTAMER
DIMER
E
C
50
 (µ
g/
m
L)
Antibodies
Human HumanRabbit Rabbit
Antibodies
Human HumanRabbit Rabbit
C
D
180
116
90
66
MW
(kDa)
180
116
90
66
MW
(kDa)2-
25
2-
18
1-
85
1-
12
5
1-
15
0
1-
10
3
57
.4
27
6.
1
70
.7
12
4.
4
27
0.
7
31
6.
2
32
4.
4
1-
32
3-
15
3-
16
15
.1
58
.5
22
3.
4
34
7.
3
FIG 1 Biochemical characterizations of MAbs speciﬁc for the pentameric complex. (A and B) To evaluate the
reactivity of selected MAbs to virus particles measured by ﬂow cytometry, V160 virus with restored expression of
the pentameric gH complex (A) and AD169 virus (B) was mixed with each MAb as indicated and then stained with
ﬂuorescence-labeled secondary antibody. The control samples were incubated with polyclonal antibodies from a
seronegative donor. Antibodies that bound to both viruses are indicated in red. The data shown are representative
of two experiments. (C) Relative binding afﬁnity was determined by quantitative ELISA and is expressed as EC50,
which is deﬁned as the IgG concentration needed to achieve 50% maximal binding signal. EC50s were determined
by four-parameter curve ﬁtting, and if there was poor ﬁt, an arbitrary EC50 of 100 g/ml was assigned. Recombinant
pentameric complex (PENTAMER) or gH/gL homodimer (DIMER) were made based on the viral sequence of the
Towne strain. (D) Western blot analysis of MAbs to denatured and reduced AD169 virus antigens.
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pentamer at domain 2, while this Fab also bound to the gH/gL homodimer at the inner
domain, which was known to comprise gL and the N terminus of gH (33). It suggested
that domain 1 was likely comprised of pUL128-131, domain 2 of gL and the N terminus
of gH, and domain 3 of the C terminus of gH, consistent with a previous report (33). The
crystal structure of Epstein-Barr virus (EBV) gH/gL (PDB 3PHF), which shares 24%
sequence similarity with HCMV gH/gL (39), can be overlaid on the 2D class image of
pentamer-270.7, supporting the assignment for domains 2 and 3. Site 1 to 4 antibodies
were found to target the tip of domain 1, consistent with the observation that site 1 to
4 antibodies bound to the pentamer only and not to the gH/gL stalk region (Fig. 1C).
Site 5 MAb 1-32 targeted one end of domain 2, while site 6 MAb 270.7 targeted the
TABLE 1 Summary of pairwise antibody inhibitiona
Antibody 1
Pairwise inhibition (%) with indicated antibody 2
S1b S2 S3 S4 S5 S6 S7
2-25c 2-18 1-85 1-150 1-103 57.4 276.1 1-32 70.7 124.4 270.7 316.2 324.4 3-7 3-15 3-16
2-25 104 87 7 17 4 15 25 2 29 1 10 1 4 9 10 6
2-18 117 97 10 12 8 8 31 1 6 11 6 3 1 16 15 17
1-85 4 14 87 117 27 29 2 16 36 24 27 29 17 27 33 37
1-150 22 10 61 104 26 19 12 11 32 22 29 22 12 0 6 2
1-103 20 10 6 49 89 4 2 12 31 22 35 28 19 12 7 38
57.4 13 14 26 12 29 93 82 41 35 25 17 19 22 8 10 13
276.1 32 17 6 17 1 84 92 7 15 5 14 1 7 0 4 3
1-32 33 1 18 4 15 57 11 91 87 7 97 78 6 8 7 10
70.7 43 36 31 35 23 35 30 64 84 76 99 89 94 27 26 25
124.4 2 7 18 6 9 13 4 20 82 94 97 79 96 11 10 8
270.7 40 32 26 33 13 28 18 57 72 70 95 78 97 24 23 17
316.2 9 23 26 31 20 12 5 59 82 87 109 92 103 18 18 19
324.4 43 24 26 37 24 35 30 32 76 78 93 80 94 24 27 29
3-7 44 51 35 6 27 20 12 10 38 35 16 21 14 91 102 97
3-15 2 12 10 29 7 6 14 1 1 11 3 3 5 81 97 86
3-16 21 17 16 22 6 11 18 5 2 1 4 7 5 79 95 88
aBiosensors coated with recombinant soluble pentameric complex were mock treated (PBS) or saturated with 15 g/ml antibody 1 prior to exposure to 15 g/ml
antibody 2. If antibodies 1 and 2 compete for binding, binding of antibody 2 will be decreased by pretreatment with antibody 1 in comparison to mock treatment.
The percentage of inhibition for each antibody 2 was calculated by normalizing these signal decreases to the total binding signal in mock treatment. Inhibition of
70% is shaded. Negative signal indicated that antibody 2 binding increased in the presence of antibody 1. It could be caused by the synergetic binding between
two independent epitopes or irrelevant antibody-antibody interaction.
bS1, site 1, etc.
cAntibody.
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magenta and gH colored gray. The images within the dotted ovals represent the indicated Fab.
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other side of domain 2. Site 7 MAb targeted the side of domain 3. Since domains 2 and
3 were preserved in gH/gL, the 2D images were consistent with the observation that
site 5 to 7 antibodies bound to both the pentamer and the gH/gL homodimer (Fig. 1C).
Three-dimensional (3D) reconstruction analyses were performed for the pentamer
bound by Fab 2-25, 1-85, and 1-103, and the 3D reconstructed density maps at a
resolution of 35 to 40 Å are shown in Fig. 3A. The crystal structures of EBV gH/gL (PDB
3PHF) and anti-gB Fab (PDB 4OSU) were manually ﬁtted into the EM 3D structure to
facilitate the interpretation (39, 40). By overlaying the gH/gL stalks of the three images
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FIG 3 EM 3D reconstruction of pentamer bound by Fabs and a summary diagram of identiﬁed immunogenic sites. (A) Structures of the
pentamer bound with Fab 2-15, Fab 1-85, or Fab 1-103 and their overlay, which was rotated 180° horizontally with respect to the
individual structures. The random conical tilt (RCT) method was used to reconstruct the 3D structures. The surface rendering was
generated using the Chimera visualization package. To aid the interpretation of the structure, the crystal structures of EBV gH/gL (PDB
3PHF) and anti-gB Fab (PDB 4OSU) were manually ﬁtted into the EM 3D map by use of Chimera. Glycoprotein gH is colored gray, and
gL is colored yellow. The numbers 1 to 3 correlate with the domains visible in the EM 2D class averages (Fig. 2). (B) A diagram showing
the four immunogenic regions (IRs) and eight immunogenic sites of the HCMV pentamer targeted by 20 neutralizing antibodies. The
arrows show the approximate positions of the immunogenic sites based on EM images.
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(Fig. 3A, left three diagrams), we found that only domain 1 could adopt different
orientations in these complexes, suggesting its orientation ﬂexibility (Fig. 3A, right
panel), consistent with a previous report (34). By comparing the three structures with
those reported previously (EMD-6436, -6347, -6438), we discovered that site 3 is a
unique site that has not been described before. Sites 1 and 2 are close to the previously
reported binding site recognized by 2C12 (34), and a competitive binding study will be
needed for a deﬁnitive comparison.
From the biochemical characterizations, pairwise antibody competition, and EM
epitope mapping, a total of four immunogenic regions (IR) on the pentameric complex
could be assigned (Fig. 3B). IR1 was composed of pUL128, pUL130, and pUL131, shown
as domain 1 in the pentamer EM 2D averages. Four nonoverlapping conformational
immunogenic sites (sites 1 to 4) were identiﬁed in IR1 from our MAb collection, and an
additional 3 or 4 unique sites exist in IR1 from other reports (34). IR2 was composed of
gL and the N terminus of gH, shown as domain 2 in the pentamer EM 2D averages. Two
partially overlapping conformational immunogenic sites were identiﬁed in IR2 (sites 5
and 6). IR3, shown as domain 3 in the pentamer 2D averages, consisted of the C
terminus of gH with one immunogenic site (site 7). IR4 resided in the ﬁrst 40 amino
acids of gH with one linear immunogenic site (site 8), commonly used to distinguish
between AD169 and Towne strains (41).
Differential inhibition of viral entry into ARPE-19 and MRC-5 cells. We next
evaluated the neutralizing function of antibodies toward each identiﬁed site, with the
speculation that each site might be engaged differently in the viral entry process. We
tested the neutralization potencies of these antibodies in both ARPE-19 and MRC-5 cells
(Fig. 4).
As expected, IR1 antibodies, all speciﬁc to the pentamer, demonstrated the most
potent antiviral function in ARPE-19 cells, with a potency more than approximately a
thousandfold higher than that of CMV hyperimmune globulin (CMV-HIG). However, this
class of antibodies could not inhibit viral entry in MRC-5 cells as previously reported for
the potent neutralizing antibodies against viral epithelial entry (27).
IR2 and IR3 antibodies, with the exception of 1-32, inhibited viral entry in both
ARPE-19 and MRC-5 cells, although they were approximately 100-fold less potent than
the majority of IR1 antibodies in ARPE-19 cells, consistent with previous observations
(27, 32, 33, 35). The fact that IR2 and IR3 antibodies showed similar potencies in both
APRE-19 and MRC-5 cells suggested that IR2 and IR3 might be involved in a common
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FIG 4 Potencies of IR1 to IR4 antibodies in neutralizing HCMV in ARPE-19 and MRC-5 cells. Representative
antibodies to each immunogenic site (and IR) were incubated in titration with HCMV. The mixtures were
then applied to ARPE-19 cells (red circles) or MRC-5 cells (blue squares), viral entry events were
documented by determining viral immediate early gene expression, and IC50s, deﬁned as the IgG
concentration to achieve 50% viral entry inhibition, were calculated using four-parameter curve ﬁtting.
The data shown are representative of three experiments.
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viral entry mechanism, such as interacting with gB, independent of cell tropism. 1-32
was a unique IR2 MAb with no antiviral activity in ﬁbroblasts. The EM 2D class average
analysis showed that Fab 1-32 was directed at domain 2 at an approximate 180° angle
against the gH/gL stalk, a binding mode signiﬁcantly different from that of other gH/gL
antibodies, such as 124.4 and 270.7 (Fig. 2). We speculated that although its binding site
was within the gH/gL domain, the unique binding angle may indicate that the epitope
of 1-32 is outside the region involved in viral entry in ﬁbroblasts, such as the interaction
with gB.
IR4 antibodies in this study inhibited viral entry into APRE-19 but not MRC-5 cells.
These antibodies were apparently different from the AP86 binding sera that bind to the
gH N-terminal linear epitope(s) and neutralize AD169 in ﬁbroblasts (42). This may
suggest that there are multiple epitopes within the gH N-terminal region, including
those recognized by IR4 antibodies, and the neutralization mechanism for these
antibodies may be complex and cell type speciﬁc.
The neutralization potencies of these antibodies in different cell types suggested
that IR1, the domain essential for viral entry in epithelial cells, was responsible for the
highly potent antibody responses and that IR2 and IR3 were necessary for antibody
responses to protect different cell types, including ﬁbroblasts. All three IRs are critical
regions to be included in rational vaccine design.
Conservation of immunogenic sites among different HCMV strains. To address
the question about antibody-mediated coverage of HCMV strains, we next determined
whether the IR-speciﬁc antibodies could neutralize genetically deﬁned clinical isolates.
Eleven isolates with full-length genome information were selected and cultured in
ARPE-19 cells (Table 2). For example, these isolates were diverse in gO sequences, as
previously reported (43), and the average amino acid distance for gO among these
strains to that in V160 was calculated to be 20.3% (Table 3). However, these strains
shared relatively high similarity to the vaccine strain when their sequences of the
pentameric complex were compared, with amino acid distances averaging 0.2 to 2.3%
(Table 3).
These isolates, along with two laboratory strains, were then tested in viral neutral-
ization assays in ARPE-19 cells (Fig. 5). IR1, IR2, and IR3 antibodies neutralized all HCMV
strains tested, consistent with the sequence similarity analysis of the pentameric
complex and suggesting that sites 1 to 7 were highly conserved among these strains.
In contrast, IR4 antibodies showed variable potencies against different strains, suggest-
ing that antibodies to site 8 were strain speciﬁc. Because of its strain speciﬁcity,
synthetic peptides corresponding to site 8 have been used as tools for serological
conﬁrmation of superinfection (41). The neutralization of these viral strains was con-
sistent with the observation that most of our antibodies were screened and selected
based on neutralization and were found to target the antigens constituting the
TABLE 2 Clinical isolates and laboratory HCMV strains
Strains
GenBank
accession no. Source of virus or reference(s)
VHL/E KX544841 55, 56
VR1814 GU179289 28, 57, 58
VR3908 KX544833 9
VR7863 KX544838 9
VR5235 KX544837 9
VR5022 KX544835 9
UxcA KX544840 59
NR KX544831 Isolated from a kidney transplant recipient and cloned in BAC
TB40/E EF999921 60, 61
SUB 22 KX544834 Isolated from a urine sample of a congenitally infected neonate
SUB 24 KX544832 Isolated from a urine sample of a congenitally infected neonate
beMAD AD169 strain from the UK (62–64) and BAC cloned and repaired
for epithelial tropism (36)
TS15-rR 59
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pentameric complex, with none to the highly variable antigens such as gO. Lastly, site
6 and 7 antibodies were effective against these strains, suggesting protection against
infection of these strains in MRC-5 cells. These results conﬁrmed the importance of sites
1 to 7 in the design of HCMV vaccines for broad strain coverage.
Site-speciﬁc antibody responses in nonhuman primates following V160 vacci-
nation. The functional map of the seven conserved immunogenic sites enabled us to
assess the quality of vaccine-induced antibody responses. As an example, ﬁve rhesus
macaques were immunized at weeks 0, 8, and 24 with the replication-defective V160
vaccine formulated with Iscomatrix adjuvant. Immune sera were evaluated in viral
neutralization assays in ARPE-19 cells. The epithelial neutralizing titers peaked after
three vaccinations at week 26 and were sustained through week 64 (Fig. 6A).
To assess whether the immune sera contained antibodies with speciﬁcity to each
immunogenic site, we measured the antibody-binding inhibition titer (last dilution of
serum that inhibits 50% of the antibody binding [AbI50]) of each of the immune sera
at weeks 0, 26, and 36 against the panel of probe antibodies from six sites. Site 3 was
excluded from this analysis, as neither the rhesus immune sera nor CMV-HIG could
compete effectively against MAb 1-103 binding to the pentamer in ELISA (data not
TABLE 3 Protein distance analysis on selected antigens between clinical isolates and V160
Clinical isolate
% Similarity with indicated V160 antigena
gB gO gH gL pUL128 pUL130 pUL131
VHL/E 4.1827 23.2435 3.6864 1.9343 0.6098 1.9075 0.0002
VR1814 5.1331 15.4296 0.6727 1.9313 1.2091 2.4834 0.0486
VR3908 4.1849 20.2599 3.2649 1.9343 1.2091 2.8977 0.0074
VR7863 4.1849 22.9828 3.6831 1.5545 1.8242 1.6592 0.0071
VR5235 4.1849 20.5298 2.5922 1.5545 1.2093 2.8766 0.0069
VR5022 4.2992 22.9828 3.6831 1.5545 1.8242 0 0.0053
UXCA 4.0721 20.3977 0.5386 0.7754 1.8242 0.78 0.0045
NR 4.5172 28.365 3.4305 1.9343 1.2091 3.3916 0.7784
TB40E 4.4039 15.4163 0.535 1.5545 1.8242 1.6592 0.0038
SUB 22 4.2992 22.9828 3.6831 1.9343 1.8242 0 0
SUB 24 4.2992 22.9828 3.6831 2.3307 1.8242 0 0
Global 3.520 0.007 20.255 0.029 2.259 0.006 1.582 0.003 1.362 0.003 1.340 0.005 0.205 0.001
aProtein distances were estimated using the algorithm within PhyML using a PAM model of molecular evolution. The values in the table were converted from a
distance by taking 1 minus the distance and multiplying it by 100 to arrive at a percent similarity. Global values are the average percentage of similarity among
complete viral sequences obtained from NCBI GenBank (n  194).
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FIG 5 Potencies of antibodies in neutralizing 11 clinical isolates and 2 laboratory strains in ARPE-19 cells.
Representative antibodies from each immunogenic site were incubated in titration with HCMV virus and
then applied to ARPE-19 cells. The viral entry events were documented by immune staining of viral
immediate early gene expression 24 h later. IC50s shown on the y axis were calculated using four-
parameter curve ﬁtting. Antibody designations and their classiﬁcation to IR regions are marked on the
x axis. CMV-HIG was included as a reference. Strain information is given in Table 2. The data shown are
representative of two experiments.
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shown). At week 0, none of the ﬁve monkeys had any preexisting AbI50 titer, whereas
at week 26, all four monkeys tested demonstrated robust antibody responses to the six
sites (Fig. 6B). Although at week 36, the vaccine induced-antibody responses waned in
all cases, the AbI50 titer for site 4 was retained in four monkeys tested and the AbI50
titers for sites 1 and 7 were retained in three of the four monkeys tested. The results
demonstrated that the vaccination elicited antibodies targeting multiple sites of the
pentameric complex, suggesting the potential to protect against viral infection in
epithelial cells (site 1, 2, and 4 antibodies) and ﬁbroblasts (site 6 and 7 antibodies) based
on the functional analysis of MAbs in Fig. 4.
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rhesus macaques immunized with V160 HCMV vaccine. The vaccine was administered at week 0, 8, and
24 (red arrowheads), and sera collected at the indicated time points were evaluated for neutralizing
activities in ARPE-19 cells. The neutralizing titers were determined by reciprocal serum dilutions to
achieve 50% viral entry reduction. The data shown are representative of two experiments. (B) AbI50 titers
of rhesus immune sera in comparison with CMV-HIG. An arbitrary number of 1 was assigned to the serum
if there was no detectable activity. The horizontal black bars represent the geometric mean AbI50 titers
to six sites. Sera from A10L106 at week 26 and A10R088 at week 36 were not available for testing. (C)
Neutralization titers of four immune sera at week 36 against 11 clinical isolates and 2 laboratory strains
in ARPE-19 cells. The legend symbols for HCMV isolates are as shown in Fig. 5. In panels B and C, CMV-HIG
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Next, we compared the site-speciﬁc antibody responses in the rhesus immune sera
with those from the natural infection in humans. Since CMV-HIG is prepared from the
plasma of donors with high antibody titers against HCMV and has been evaluated for
prophylaxis against congenital HCMV infection (44, 45), we measured the 50% inhibi-
tory concentrations (IC50s) of CMV-HIG and calculated the AbI50 titers that represent the
average serum titers from the natural infection (Fig. 6B). The comparison demonstrated
that the antibody responses induced by V160 targeted sites similar to those from
natural infection, and the peak AbI50 titers at week 26 were in the range of the CMV-HIG
concentrations.
Not only did the AbI50 titer show the quality of antibody responses, it was also a
good indicator of serum antiviral functions, as the geometric mean (GM) of AbI50 titers
toward the six sites closely correlated with the neutralization titers, with a correlation
coefﬁcient of 0.93 (R2  0.87, P  0.0008).
Lastly, we evaluated the ability of rhesus immune sera to cross-neutralize the clinical
isolates. As shown in Fig. 6C, all 4 of the week 36 immune sera tested could neutralize
these viral isolates, with potencies ranked similar to their AbI50 titers and matched
closely the CMV-HIG concentrations. This result conﬁrmed that V160 vaccination in
nonhuman primates can elicit antibodies with antiviral activity against the clinical
isolates and also suggested that the competition against all six probe antibodies could
serve as a surrogate for assessing the ability of immune sera to neutralize potentially
genetically diverse ﬁeld strains.
DISCUSSION
Because of its importance to HCMV vaccine development, we set out to analyze the
quality of antiviral antibodies by vaccination compared to those by natural infection.
Our work led to a map of immunogenic sites of the HCMV pentamer, a viral antigen
complex known to be targeted by potent neutralizing antibodies. The abundance of
immunogenic sites in IR1 was consistent with an observation reported recently (33), as
well as our previous report that the soluble pentamer, and not the gH/gL homodimer,
can deplete over 75% of the epithelial neutralizing activity in CMV-HIG (38).
The geometric mean AbI50 titer for the six sites served as an indicator of the quality
of vaccine-induced antibodies, as it suggested not only antiviral potency but also
ARPE-19 or MRC-5 cell type-speciﬁc protection in vitro. The absolute value of AbI50 may
also be used to infer the quantity of each type of antibody in the immune sera. For
example, when CMV-HIG competes with the six probe antibodies at 0.05 g/ml, the
AbI50 titers of CMV-HIG range from 15 to 47 and the IC50s of CMV-HIG in the viral
neutralization assay range from 210 to 650 g/ml. By this estimate, only a tiny fraction
of total CMV-HIG (estimate, 0.01 to 0.02%) binds to each immunogenic site with a
strength similar to that of the probe antibodies. Nevertheless, the marginal presence of
0.01 to 0.02% of a highly potent antibody, such as site 1 antibody, which has an IC50
of 0.2 ng/ml in the viral neutralization assay, may contribute to the majority of
neutralization activity of CMV-HIG (IC50, approximately 1,000 ng/ml). Therefore, al-
though the AbI50 titers appeared low in this study, they revealed infrequent but highly
potent neutralizing antibodies in the immune sera.
Our collection of antibodies was derived from both humans with natural HCMV
infection and an animal vaccinated with a whole virion vaccine, and their in vitro
potencies against viral infection were benchmarked to the potency of CMV-HIG. In this
regard, these antibodies are useful tools to identify the protective component within
the vaccine-induced immune sera. Previously, Lilleri et al. reported that in pregnant
women with primary HCMV infection, early emergence (30 days) of an antibody
response to epitopes in IR1 is associated with a signiﬁcantly reduced risk of intrauterine
HCMV transmission (46). Their study provided evidence that antibodies with IR1
speciﬁcity are a correlate to protection against maternal-fetal transmission. CMV-HIG
has been evaluated for the prevention of congenital HCMV infection but with efﬁcacies
of 31% and 60% in two separate studies (44, 45), respectively, and our results suggest
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that CMV-HIG contains less than 0.02% of IR1 antibodies. In this regard, IR1-speciﬁc
MAbs, if used as therapeutics, may provide better clinical outcomes than CMV-HIG.
Antibodies mapped to seven out of eight immunogenic sites of the pentamer
demonstrated neutralizing coverage to a panel of 11 clinical isolates. This result
suggested that antibodies from natural infection were likely protective in vitro against
the strains causing HCMV superinfection. Thus, HCMV-seropositive individuals who
succumb to superinfection may have a deﬁciency in their natural immunity to HCMV.
A serological survey of 360 HCMV-seropositive women revealed a geometric mean
neutralizing titer for the cohort of 1:7,500; however, about 5% of the subjects had
neutralizing titers below 1:1,000 (47). In addition, it is not clear whether defective
cell-mediated immunity in HCMV-seropositive subjects plays a role in superinfection.
Second, superinfection may be related to viral titers of the inoculum. A human
challenge study in which the HCMV-seropositive subjects were challenged with a
pathogenic Toledo strain was conducted, and the results support this hypothesis, as
HCMV seropositivity was protective against challenge inocula of 10 and 100 PFU, but
not 1,000 PFU, of Toledo virus (48). Lastly, it is also possible that serum neutralizing
potency measured in vitro may not truly reﬂect antiviral immunity in the host.
In conclusion, we identiﬁed four IRs containing eight immunogenic sites on the
pentamer, an antigen for neutralizing antibodies. The functional characterization of
these sites enabled the evaluation of the quality of vaccine-induced antibody re-
sponses. Rhesus macaques vaccinated with V160 generated diverse antibody responses
to the pentamer, and their immune sera demonstrated neutralization against a panel
of clinical HCMV isolates. The analysis of site-speciﬁc antibody responses presents a
useful tool to analyze V160-induced immune responses for their role in vaccine efﬁcacy
against congenital HCMV infection.
MATERIALS AND METHODS
Antibody generation. Rabbit MAbs were isolated from an animal immunized with AD169 revertant
virus as previously reported (27). Human MAbs were isolated from memory B cells from three healthy
individuals with natural HCMV infection. Brieﬂy, memory B cells were enriched using an EasySep memory
B-Cell kit (StemCell). Enriched memory B cells were cultured in limiting dilution in 96-well U-bottom
plates with gamma-irradiated feeder cells expressing human CD40L in complete RPMI medium supple-
mented with interleukin-21 (50 ng/ml) (Invitrogen). The supernatant was collected at day 14 and
screened for viral neutralization and/or binding activity as described previously (27). Total RNA from the
cells in the positive wells was isolated and converted to cDNA using a reverse transcription kit
(Invitrogen), and the IgG genes were recovered by PCR using primers that have been described
previously (49). Recombinant antibodies were expressed by transient transfection in HEK293 cells and
puriﬁed by protein A afﬁnity chromatography (50). The purity and integrity of the antibodies were
assessed by SDS-PAGE.
Biochemical characterizations. For Western blot analysis, denatured and reduced V160 samples
were analyzed on a Simon capillary Western blot system (ProteinSimple) as previously described (51).
Brieﬂy, the V160 sample was mixed with sample buffer containing SDS and dithiothreitol (DTT) and then
heated for 10 min at 70°C. The SDS-PAGE separation occurred in capillary and viral antigens that were
probed with each primary antibody for 90 min and then for 60 min with secondary antibody, either
anti-rabbit IgG with horseradish peroxidase (HRP) from ProteinSimple or anti-human IgG with HRP from
Jackson ImmunoResearch. The chemiluminescence signal was measured at six different exposure times.
For ELISA, recombinant dimer or pentamer was immobilized at 1 g/ml in phosphate-buffered saline
(PBS) on 96-well FluoroNunc MaxiSorp plates at 4°C overnight. The plates were then blocked with 3%
nonfat milk in PBS–0.05% Tween 20. MAbs in titration in PBS were incubated for 1.5 h, and the plates
were washed afterwards and then incubated with HRP-conjugated goat anti-rabbit or anti-human IgG
(Southern Biotech) for 30 to 60 min. A ﬂuorogenic HRP substrate, 10-acetyl-3,7-dihroxyphenoxazine
(ADHP) (Virolabs), was added at 100 l per well for 3 to 5 min to generate resoruﬁn, and the ﬂuorescent
signals with excitation at 531 nm and emission at 595 nm were measured (Victor III; PerkinElmer). The
effective concentration of MAb to achieve 50% maximal binding (EC50) was calculated using four-
parameter curve ﬁtting as described previously (27). Antibody binding to HCMV particles measured by
ﬂow cytometry was conducted as described previously (37). Brieﬂy, V160 or AD169 virus preparations
were incubated with each MAb, followed by the removal of the unbound MAb, incubation with Alexa
Fluor 488-labeled secondary antibody, and removal of the unbound secondary antibody. The ﬂow
cytometer was triggered on the side light scatter signal from the HCMV particles. Negative human and
rabbit polyclonal IgG were used as controls.
Pairwise antibody competition using biolayer interferometry. The competition assay was per-
formed on an Octet HTX using NTA Biosensors (FortéBio). Antibodies were diluted to 15 g/ml in PBS and
placed into 384 tilted-bottom microplates. All biosensors were rehydrated with PBS for at least 10 min,
loaded with recombinant pentamer (38) at 5 g/ml in PBS for 900 s, and then washed in PBS for 60 s.
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A group of 16 biosensors was loaded for 2,000 s with either PBS as the control or antibody 1 at 15 g/ml
to achieve saturation. The biosensors were then washed in PBS for 60 s and transferred to wells
containing different antibodies (antibody 2) to allow 1,500 s of total binding time. The decrease of
antibody 2 association in the presence of antibody 1 was normalized by the total binding in the absence
of antibody 1 (PBS control) in order to calculate the percentage of competition. The procedure was
repeated for the remaining 15 antibodies as for antibody 1.
Electron microscopy. Fabs were generated from the selected antibodies and mixed with the
pentamer or the gH/gL dimer at a 5:1 molar ratio for 1 h. The complexes were then separated by size
exclusion chromatography and applied to glow discharg holey carbon grids and stained with 2% uranyl
formate. The grids were imaged using an FEI Tecnai T12 electron microscope operating at 120 keV and
equipped with an FEI Eagle 4k  4k charge-coupled-device (CCD) camera. Tilt pair images (0°, 60°) were
recorded using Leginon at a nominal magniﬁcation of 67,000 with a nominal underfocus of 2 m to 1
m and electron doses of 25 to 30 e/A2.
Image processing and model reconstructions were performed using the Appion software package.
Individual particles were selected using automated picking protocols on both untilted and tilted images,
and the untilted particles were subjected to several rounds of reference-free alignment and classiﬁcation
using the XMIPP processing package. Random conical tilt (RCT) reconstructions were performed using
particle pairs from exemplar class averages to obtain 3D maps of the complexes. The nominal resolution
of the 3D maps is 35 to 40 Å, with the resolution criterion Fourier shell correlation equal to 0.5 (FSC0.5).
The Chimera visualization package was used to produce the surface rendering of each complex and to
ﬁt the X-ray structure of EBV gH/gL (PDB 3PHF) into the EM maps.
Virus stains and viral neutralization in ARPE-19 and MRC-5 cells. AD169 revertant virus has been
described previously (36, 52), and primary clinical isolates were recently isolated and cultured or obtained
from James Waldman, Maria Revello, and Eain Murphy. The virus was culture adapted in ARPE-19 cells
and puriﬁed by ultracentrifugation as previously described (47). The viral infectivity was assessed by a
50% tissue culture infective dose (TCID50) assay. The viral neutralization assay based on immunostaining
was described previously (53).
Vaccination study. Rhesus macaques (Macaca mulatta) were maintained at the New Iberia Research
Center (NIRC), New Iberia, LA. All animal studies were conducted in accordance with the Guide for the
Care and Use of Laboratory Animals, and the study protocols were approved by Institutional Animal Care and
Use committees. Rhesus macaques were anesthetized, and the vaccines were delivered intramuscularly in
0.5-ml volumes into deltoid muscles. V160 vaccine has been described previously (36) and was formulated
prior to injection with 30 g/dose Iscomatrix adjuvant provided by CSL Ltd. (Victoria, Australia).
AbI50 titer. Competition ELISA was used to determine the serum antibody-binding inhibition (AbI50)
titer against a panel of seven antibodies (2-18, 1-125, 1-103, 57.4, 1-32, 124.4, and 3-16), each repre-
senting one immunogenic site. The recombinant pentamer complex was immobilized at 0.3 g/ml in PBS
on 96-well FluoroNunc MaxiSorp plates at 4°C overnight. The plates were then blocked with 3% nonfat
milk in PBS–0.05% Tween 20. Rhesus serum in titration in PBS was mixed with 0.05 g/ml of either
biotinylated human antibody or unbiotinylated rabbit antibody, and then the mixture was incubated in
the precoated plates for 1.5 h. The plates were washed afterwards and then incubated with HRP-
conjugated detection agents, either streptavidin (BD Pharmingen) or goat anti-rabbit IgG (Southern
Biotech), for 30 to 60 min. ADHP was added at 100 l per well for 3 to 5 min to generate resoruﬁn, and
the ﬂuorescent signals with excitation at 531 nm and emission at 595 nm were measured (Victor III;
PerkinElmer). AbI50 titers were deﬁned as the last dilution of serum that inhibits 50% of the antibody
binding.
A similar competition ELISA was used to determine the IC50 of CMV-HIG in inhibiting the same panel
of probe antibodies binding to their corresponding epitopes. Inhibition curves were constructed for each
immunogenic site, and the four-parameter logistic curve ﬁtting was done to extract IC50 (g/ml) values.
The average human serum IgG concentration of 10,000 g/ml was then divided by the IC50s to derive
AbI50 titers of CMV-HIG.
Accession number(s). The sequence information for some viral strains listed in Table 2 was
determined by next-generation sequencing, and the sequences have been described elsewhere (54).
These strains include VHL/E (GenBank accession number KX544841), VR3908 (KX544833), VR7863
(KX544838), VR5235 (KX544837), VR5022 (KX544835), UxcA (KX544840), NR (KX544831), sub 22
(KX544834), and sub 24 (KX544832).
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